Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | FKBP-type peptidylprolyl isomerase | 0.0052 | 0.1155 | 0.5 |
Toxoplasma gondii | peptidyl-prolyl isomerase FKBP12, putative | 0.0052 | 0.1155 | 0.5 |
Onchocerca volvulus | 0.0053 | 0.1199 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0326 | 0.8478 | 0.8636 |
Giardia lamblia | FKBP-type peptidyl-prolyl cis-trans isomerase | 0.0377 | 0.9817 | 1 |
Loa Loa (eye worm) | FKBP5 protein | 0.0377 | 0.9817 | 1 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-30 | 0.0052 | 0.1155 | 0.1177 |
Schistosoma mansoni | immunophilin FK506 binding protein FKBP12 | 0.0377 | 0.9817 | 0.9817 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-33 | 0.0052 | 0.1155 | 0.1177 |
Schistosoma mansoni | fk506 binding protein | 0.0052 | 0.1155 | 0.1155 |
Mycobacterium leprae | PROBABLE TRIGGER FACTOR (TF) PROTEIN TIG | 0.0052 | 0.1155 | 0.5 |
Toxoplasma gondii | peptidyl-prolyl cis-trans isomerase, FKBP-type domain-containing protein | 0.0052 | 0.1155 | 0.5 |
Brugia malayi | FKBP-type peptidyl-prolyl cis-trans isomerase-59, BmFKBP59 | 0.0378 | 0.986 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0052 | 0.1155 | 0.1177 |
Schistosoma mansoni | immunophilin | 0.0384 | 1 | 1 |
Trypanosoma brucei | peptidyl-prolyl cis-trans isomerase, putative | 0.0377 | 0.9817 | 1 |
Leishmania major | FKBP-type peptidyl-prolyl cis-trans isomerase, putative | 0.0052 | 0.1155 | 0.1177 |
Toxoplasma gondii | peptidyl-prolyl cis-trans isomerase, FKBP-type domain-containing protein | 0.0052 | 0.1155 | 0.5 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-13 | 0.0052 | 0.1155 | 0.1177 |
Trichomonas vaginalis | immunophilin, putative | 0.0377 | 0.9817 | 1 |
Echinococcus granulosus | FK506 binding protein 2 | 0.0052 | 0.1155 | 0.1155 |
Giardia lamblia | 70 kDa peptidylprolyl isomerase, putative | 0.0377 | 0.9817 | 1 |
Echinococcus multilocularis | fk506 binding protein | 0.0377 | 0.9817 | 0.9817 |
Trichomonas vaginalis | fk506 binding protein, putative | 0.0052 | 0.1155 | 0.1177 |
Leishmania major | fk506-binding protein 1-like protein | 0.0377 | 0.9817 | 1 |
Echinococcus multilocularis | peptidyl prolyl cis trans isomerase FKBP4 | 0.0332 | 0.8618 | 0.8618 |
Trypanosoma brucei | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0377 | 0.9817 | 1 |
Trichomonas vaginalis | fk506-binding protein, putative | 0.0377 | 0.9817 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.1155 | 0.1177 |
Onchocerca volvulus | 0.0052 | 0.1155 | 0.9638 | |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP1A | 0.0377 | 0.9817 | 0.9817 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0052 | 0.1155 | 0.1177 |
Trypanosoma brucei | macrophage infectivity potentiator, precursor, putative | 0.0052 | 0.1155 | 0.1177 |
Plasmodium falciparum | peptidyl-prolyl cis-trans isomerase FKBP35 | 0.0377 | 0.9817 | 1 |
Mycobacterium ulcerans | FK-506 binding protein, peptidyl-prolyl cis-trans isomerase | 0.0377 | 0.9817 | 1 |
Leishmania major | peptidylprolyl isomerase-like protein | 0.0377 | 0.9817 | 1 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-12 | 0.0377 | 0.9817 | 1 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type , putative | 0.0384 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0052 | 0.1155 | 0.1177 |
Mycobacterium tuberculosis | Probable trigger factor (TF) protein Tig | 0.0052 | 0.1155 | 0.5 |
Trichomonas vaginalis | fk506-binding protein, putative | 0.0052 | 0.1155 | 0.1177 |
Chlamydia trachomatis | peptidyl-prolyl cis-trans isomerase | 0.0052 | 0.1155 | 0.5 |
Toxoplasma gondii | peptidyl-prolyl cis-trans isomerase, FKBP-type domain-containing protein | 0.0052 | 0.1155 | 0.5 |
Leishmania major | peptidyl-prolyl cis-trans isomerase, putative | 0.0052 | 0.1155 | 0.1177 |
Plasmodium vivax | 70 kDa peptidylprolyl isomerase, putative | 0.0377 | 0.9817 | 1 |
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0377 | 0.9817 | 1 |
Brugia malayi | FKBP-type peptidyl-prolyl cis-trans isomerase-12, BmFKBP-12 | 0.0377 | 0.9817 | 0.995 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0377 | 0.9817 | 1 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP4 | 0.0332 | 0.8618 | 0.8618 |
Schistosoma mansoni | hypothetical protein | 0.0052 | 0.1155 | 0.1155 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0377 | 0.9817 | 1 |
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0377 | 0.9817 | 1 |
Echinococcus granulosus | FK506 binding protein 8 38 kDa | 0.0052 | 0.1155 | 0.1155 |
Schistosoma mansoni | immunophilin | 0.0384 | 1 | 1 |
Treponema pallidum | peptidyl-prolyl cis-trans isomerase, FKBP-type, 22 kDa (fklB) | 0.0377 | 0.9817 | 1 |
Trypanosoma brucei | peptidyl-prolyl cis-trans isomerase, putative | 0.0052 | 0.1155 | 0.1177 |
Wolbachia endosymbiont of Brugia malayi | FKBP-type peptidylprolyl isomerase | 0.0052 | 0.1155 | 0.5 |
Echinococcus multilocularis | 0.0052 | 0.1155 | 0.1155 | |
Echinococcus multilocularis | FK506 binding protein 8, 38 kDa | 0.0059 | 0.1339 | 0.1339 |
Trypanosoma brucei | FKBP-type peptidylprolyl cis-trans isomerase, putative | 0.0052 | 0.1155 | 0.1177 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0377 | 0.9817 | 1 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type, putative | 0.0384 | 1 | 1 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0377 | 0.9817 | 1 |
Schistosoma mansoni | immunophilin | 0.0332 | 0.8618 | 0.8618 |
Trichomonas vaginalis | fk506-binding protein, putative | 0.0052 | 0.1155 | 0.1177 |
Leishmania major | peptidyl-prolyl cis-trans isomerase, macrophage infectivity potentiator precursor, putative | 0.0052 | 0.1155 | 0.1177 |
Echinococcus multilocularis | peptidyl prolyl cis trans isomerase FKBP4 | 0.0384 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 5.23 % | Induction of apoptosis in human K562 cells assessed as accumulation at subG1 phase at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 5.23 % | Induction of apoptosis in human K562 cells assessed as accumulation at subG1 phase at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 22.7 % | Cell cycle arrest in human K562 cells by accumulation at G0/G1 phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 22.7 % | Cell cycle arrest in human K562 cells by accumulation at G0/G1 phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 29.8 % | Cell cycle arrest in human K562 cells by accumulation at G2/M phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 29.8 % | Cell cycle arrest in human K562 cells by accumulation at G2/M phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 47.5 % | Cell cycle arrest in human K562 cells by accumulation at S phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
Activity (functional) | = 47.5 % | Cell cycle arrest in human K562 cells by accumulation at S phase cell at 50 uM after 24 hrs relative to control | ChEMBL. | 17485212 |
GI50 (functional) | = 1.8 uM | Cytotoxicity against human SR cells | ChEMBL. | 17485212 |
GI50 (functional) | = 1.8 uM | Cytotoxicity against human SR cells | ChEMBL. | 17485212 |
GI50 (functional) | = 13 uM | Cytotoxicity against human DU145 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 13 uM | Cytotoxicity against human DU145 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 13.1 uM | Cytotoxicity against human HCT15 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 13.1 uM | Cytotoxicity against human HCT15 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 13.9 uM | Cytotoxicity against human LOX IMVI cells | ChEMBL. | 17485212 |
GI50 (functional) | = 13.9 uM | Cytotoxicity against human LOX IMVI cells | ChEMBL. | 17485212 |
GI50 (functional) | = 15 uM | Cytotoxicity against human OVCAR3 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 15 uM | Cytotoxicity against human OVCAR3 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 16.6 uM | Cytotoxicity against human MDA-MB-435 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 16.6 uM | Cytotoxicity against human MDA-MB-435 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 19 uM | Cytotoxicity against human SF295 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 19 uM | Cytotoxicity against human SF295 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 20.3 uM | Cytotoxicity against human K562 cells | ChEMBL. | 17485212 |
GI50 (functional) | = 20.3 uM | Cytotoxicity against human K562 cells | ChEMBL. | 17485212 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.